Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997601 | 1.00 | NPY5R (0.69) | NPY5RTACR1 | |
| SCHEMBL30425441 | 0.84 | NOTUM (0.60) | NPY5R | |
| SCHEMBL12568547 | 0.83 | NPY5R (0.58) | NPY5RTACR1 | |
| SCHEMBL6214008 | 0.83 | NPY5R (0.50) | NPY5RTACR1 | |
| SCHEMBL6213077 | 0.83 | NPY5R (0.50) | NPY5RTACR1 | |
| SCHEMBL5471053 | 0.82 | NPY5R (0.66) | NPY5RTACR1 | |
| SCHEMBL5471049 | 0.82 | NPY5R (0.66) | NPY5RTACR1 | |
| SCHEMBL6214081 | 0.82 | NPY5R (1.00) | NPY5R | |
| SCHEMBL6214084 | 0.82 | NPY5R (1.00) | NPY5R | |
| SCHEMBL31572868 | 0.82 | NOTUM (0.55) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960402-B2 | Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-1795527-B1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1129089-B1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040063942-A1 | Spiro-indolines as Y5 receptor antagonists | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-6638942-B1 | Useful in the treatment of obesity and the complications associated therewith. | MERCK & CO., INC. | 2003-10-28 | — | — | US | disclosed |
| US-6495559-B2 | FOR THERAPY OF OBESITY | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | MSD K.K. (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6313298-B1 | OBESITY, DIETETICS; NEUROPEPTIDE Y ANTAGONISTS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| US-6191160-B1 | DIETETICS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063942-A1 | Spiro-indolines as Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885TACR1 62/4885 |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885TACR1 61/4885 |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | NPY5R 75/4885TACR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.